Noxxon Pharma is set to continue subject enrolment in the GLORIA clinical trial of NOX-A12 in individuals with brain cancer (glioblastoma).
The move comes after the Data Safety Monitoring Board (DSMB) analysed safety results from the preliminary four-week treatment with NOX-A12 plus radiotherapy and bevacizumab in the first subject in the expansion arm of the trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The DSMB concluded that the treatment is safe and suitable to progress recruitment to enrol five more subjects into this arm as per the protocol of the trial.
Furthermore, the company noted that the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) granted approval for the third expansion arm of the trial.
Subjects in this arm will be given NOX-A12 plus pembrolizumab, an inhibitor of programmed cell death protein 1 (PD-1) immune checkpoint, and radiotherapy.
In the GLORIA Phase I/II trial, the safety and efficacy of NOX-A12 plus radiotherapy will be analysed in recently detected glioblastoma in subjects with unmethylated MGMT promoter.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThree expansion arms of the trial will each enrol six subjects to assess NOX-A12 advantage in various treatment settings.
Arm A will study NOX-A12 plus radiotherapy in individuals with complete tumour resection.
Arm B will evaluate the treatment, along with radiotherapy and bevacizumab, in incomplete tumour resection patients while Arm C will assess NOX-A12 plus radiotherapy and pembrolizumab in subjects with incomplete tumour resection.
Noxxon Pharma CEO Aram Mangasarian said: “The three arms in the expansion of our Phase I/II study of NOX-A12 are supported by the clinical data from the GLORIA trial and are designed to explore the potential for improved benefits for patients with brain tumours.
“The combination with the anti-PD-1 inhibitor pembrolizumab is of particular interest as we expect this combination therapy to unlock a stronger and more durable immune response against the tumour.
“This is based on our previous observation that NOX-A12 drives infiltration of activated cytotoxic immune cells into brain tumour tissue.”
In March 2021, Noxxon obtained a positive recommendation from the DSMB to progress recruitment in a brain cancer study of NOX-A12 plus radiotherapy
